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Trans-ancestral GWAS of alcohol dependence reveals common 
genetic underpinnings with psychiatric disorders
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Abstract
Liability to alcohol dependence (AD) is heritable, but little is known about its complex polygenic 
architecture or its genetic relationship with other disorders. To discover loci associated with AD 
and characterize the relationship between AD and other psychiatric and behavioral outcomes, we 
carried out the largest GWAS to date of DSM-IV diagnosed AD. Genome-wide data on 14,904 
individuals with AD and 37,944 controls from 28 case/control and family-based studies were 
meta-analyzed, stratified by genetic ancestry (European, N = 46,568; African; N = 6,280). 
Independent, genome-wide significant effects of different ADH1B variants were identified in 
European (rs1229984; p = 9.8E-13) and African ancestries (rs2066702; p = 2.2E-9). Significant 
genetic correlations were observed with 17 phenotypes, including schizophrenia, ADHD, 
depression, and use of cigarettes and cannabis. The genetic underpinnings of AD only partially 
overlap with those for alcohol consumption, underscoring the genetic distinction between 
pathological and non-pathological drinking behaviors.
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INTRODUCTION
Excessive alcohol use is a leading contributor to morbidity and mortality. One in 20 deaths 
worldwide is attributable to alcohol consumption, as is 5.1% of the global burden of 
disease1. Alcohol dependence (AD), as defined by the Fourth Edition of the American 
Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)2, 
is a serious psychiatric disorder characterized by tolerance, withdrawal, loss of control over 
drinking and excessive alcohol consumption despite negative health and social 
consequences. Among alcohol drinkers, 12% meet criteria for DSM-IV AD during their 
lifetimes3. In the United States, only 25% of those with AD ever receive treatment4.
AD is moderately heritable (49% by a recent meta-analysis)5 and numerous genome-wide 
association studies (GWAS) have aimed to identify loci contributing to this genetic variance 
(see6 for a review). According to one study, common SNPs are responsible for as much as 
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30% of the variance in AD7, but few have been identified to date. Variants in the genes 
responsible for alcohol metabolism, especially ADH1B and ALDH2, have been strongly 
implicated8–13. The association between AD (and related drinking phenotypes) and 
rs1229984, a missense SNP (Arg48His) in ADH1B that affects the conversion of alcohol to 
acetaldehyde, represents one of the largest common-variant effect sizes observed in 
psychiatry, with the His48 allele accelerating ethanol metabolism and affording 
approximately 3-fold reduction in likelihood of AD across numerous studies8,10. Another 
functional polymorphism, rs671 in ALDH2 (Glu504Lys), strongly affects alcohol 
metabolism by blocking conversion of acetaldehyde to acetate and has an even stronger 
effect on risk for AD, but is rare except in some Asian populations8,12,13 ADH1B and 
ALDH2 polymorphisms, however, only explain a small proportion of the heritable variation 
in AD in populations of European or African ancestry.
In this study, the Substance Use Disorders working group of the Psychiatric Genomics 
Consortium (PGC-SUD14) compiled the largest numbers of carefully diagnosed alcohol 
dependent individuals and alcohol-exposed controls to date, from both case-control and 
family studies. These included substantial numbers of both European ancestry (EU, N = 
46,568, including 38,686 unrelated individuals) and admixed African-American ancestry 
(AA, N = 6,280, including 5,799 unrelated individuals) subjects. AD diagnoses were derived 
from clinician ratings or semi-structured interviews following DSM-IV2 criteria. Each study 
was subjected to stringent quality control (QC) before conducting GWAS within each 
population of each study, followed by a genome-wide meta-analysis. We estimated the SNP-
heritability (h2g) of AD and examine the extent to which aggregate genetic variation in AD 
is related to traits from 45 other GWAS, including continuous measures of alcohol 
consumption. We also examined whether polygenic risk scores (PRS) derived from these 
analyses predicted alcohol dependence and related measures of problem drinking in three 
independent samples.
RESULTS
GWAS meta-analyses:
The trans-ancestral discovery meta-analysis of GWAS of AD in 28 cohorts (Table 1; 
Supplementary Table S1) identified a genome-wide significant (GWS; p < 5E-8) association 
in the ADH gene cluster on chromosome 4 (Figure 1; Table 2). Examining this locus in each 
population (Figure 2), rs1229984 in ADH1B was the strongest associated variant from the 
analysis in EU (z = −7.13, p = 9.8E-13), while rs2066702, also in ADH1B, was the most 
significant variant in AA (z = −5.98, p = 2.2E-9). Trans-ancestral modelling reinforced the 
robust effects of rs1229984 and other ADH1B SNPs on liability to AD across inverse-
variance weighted, random effects, and Bayesian models (Supplementary Figure S1, 
Supplementary Table S2).
Clumping the ADH locus for linkage disequilibrium (LD; r2 < 0.1 within 500 kb) suggested 
multiple independent signals in both populations, with the differing leading alleles reflecting 
different LD structures and allele frequencies in each population (Table 2, Supplementary 
Figure S2). Conditional analyses controlling for rs1229984 and rs2066702 had limited 
power, but results showed limited attenuation of effect sizes between marginal and 
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conditional analyses, consistent with the existence of additional independent effects in the 
region (Supplementary Table S3; Supplementary Figure S3). Suggestive independent signals 
in the genotyped cohorts included trialleleic variant rs894368 (marginal z = −4.57, p = 
4.9E-6; conditional z = −4.53, p = 5.8E-6) and insertion rs112346244 (marginal odds ratio = 
0.912, SE = .024, z = −3.81, p = 1.4E-4; conditional odds ratio = 0.883, SE = .025, z = 
−5.05, p = 4.5E-7; Supplementary Table S3). Several additional variants that were prioritized 
in the conditional analysis, while not significant, were in moderate to strong LD with rs698 
(marginal odds ratio = 1.115, SE = .021, z = 5.19, p = 2.1E-7; conditional odds ratio = 
1.084, SE = .021, z = 3.78, p = 1.6E-4), a functional ADH1C variant with a role in AD8,11.
A single novel SNP on chromosome 3, rs7644567, also reached GWS in the meta-analysis 
(z = 5.68, p = 1.36E-8; Supplementary Figure S4). Potential biological associations with 
rs7644567, including chromatin contacts (Supplementary Figure S5) and cerebellar 
expression of RBMS3, are summarized in Supplementary Information A9. However, 
rs7644567 did not replicate in two independent AA samples (Yale-Penn2 and COGA 
AAfGWAS) or the independent FINRISK cohort; all three replication cohorts estimating 
effects of the minor allele in the opposite direction of the discovery meta-analysis 
(Supplementary Table S4). The SNP is also rare in most EU samples (minor allele frequency 
[MAF] < 0.01), with the current GWAS results primarily attributable to AA cohorts, along 
with FinnTwin and NAG-Fin. The EU cohorts in the discovery meta-analysis show no 
evidence of association of AD with the SNPs in strongest LD with rs7644567 in African 
(rs13098461; z = 0.27, p = 0.79) or Finnish (rs9854300; z = 0.10, p = 0.92) reference 
samples (Supplementary Information A9). Based on the clear lack of replication there is 
insufficient evidence to conclude rs7644567 is associated with AD based on the current 
results.
There was limited genome-wide evidence for heterogeneity across all cohorts, within 
ancestry, between ancestries, or between study designs within ancestry (Supplementary 
Information A8; Supplementary Figures S6–S8). Evidence for inflation from population 
stratification or other confounding was also limited in the discovery meta-analysis (lambda = 
0.962; Supplementary Figure S9) and within EU (lambda = 1.053, LD score regression 
[LDSR] intercept = 1.018) and AA (lambda = 1.007, LDSR intercept = 0.991-0.997; 
Supplementary Information A11). Gene-level association testing with MAGMA15 did not 
identify any additional significant genes in EU or AA (Supplementary Table S5, 
Supplementary Information A12), likely due to lack of power.
Heritability and genetic correlations:
Liability-scale SNP-heritability of AD was estimated at h2g = 0.090 (SE = 0.019, z = 4.80, p 
= 8.02E-7) in the meta-analysis of unrelated EU samples. Exclusion of the ADH1B locus 
did not substantially modify this estimate (h2g = 0.089, SE = 0.0185). Nominally significant 
polygenic signal for the meta-analysis of unrelated AA individuals was observed based on 
LDSR with scores computed from 1000 Genomes African populations (z = 2.12, p = 0.017), 
but the quantitative estimate of h2g was unstable depending on the choice of reference panel, 
reflecting the challenge of correctly specifying LDSR and robustly modelling LD for the AA 
population (Supplementary Information A11).
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Significant genetic correlation with AD in EU was observed for 17 traits after correction for 
multiple testing (p < 1.11E-3 for 45 tested traits; Figure 3; Supplementary Table S6). The 
largest positive correlations were with ever smoking tobacco (rg = 0.708, SE = 0.134, p = 
1.3E-7) and lifetime cannabis use (rg = 0.793, SE = 0.217, p = 2.5E-4), and with other 
psychiatric disorders, especially schizophrenia (rg = 0.357, SE = 0.054, p = 3.2E-11), ADHD 
(rg = 0.444, SE = 0.097, p = 4.2E-6), and depression (rg = 0.561, SE = 0.085, p = 3.5E-11). 
Educational attainment (rg = −0.468, SE = 0.066, p = 9.7E-13) and age at first birth (higher 
values indicate that participants were older when they had their first child; rg = −0.626, SE = 
0.104, p = 2.0E-9) showed significant inverse genetic correlation with AD suggesting that 
liability to AD risk was genetically related to lower educational attainment and lower age at 
which the participant had his or her first child.
Unexpected patterns of genetic correlation were observed when comparisons were made to 
other alcohol-related measures, indicating that those measures reflect aspects of alcohol use 
that are genetically distinguishable. AD was genetically correlated with alcohol consumption 
in a meta-analysis of the Alcohol Genome-wide Association (AlcGen) and Cohorts for 
Aging and Research in Genomic Epidemiology Plus (CHARGE+) consortia16 (rg = 0.695, 
SE = 0.155, p = 6.9E-6) but only modestly with alcohol consumption from the recent large 
UK Biobank analysis17 (rg = 0.371, SE = 0.092, p = 5.2E-5). No significant genetic 
correlation was observed between AD and a recent GWAS of the Alcohol Use Disorders 
Identification Test (AUDIT) in a 23andMe cohort18 (rg = 0.076, SE = 0.171, p = 0.65), 
perhaps due to the low levels of drinking and drinking-related problems in that population18. 
AD is, however, nominally genetically correlated with GWAS of delay discounting in the 
23andMe sample19 (rg = 0.487, SE = 0.178, p = 6.0E-3).
Association with ADH1B expression:
Based on the strong observed association with rs1229984 and rs2066702 we examined 
whether other variants affecting ADH1B expression (eQTLs) were also associated with AD 
using GTEx V7 results (https://www.gtexportal.org/)20. Three variants, rs11939328 (EU p = 
0.78, AA p = 0.98, Trans p = 0.78), rs10516440 (EU p = 3.97E-6, AA p = 1.97E-3, Trans p 
= 4.72E-8), and rs7664780 (EU p = 0.87, AA p = 0.083, Trans p = 0.405), were selected 
after LD-informed clumping and the exclusion of variants in LD (r2>0.1) with the GWS 
coding alleles rs1229984 and rs2066702. Of these, only rs10516440 (AD conditional 
analyses: EU p = 1.34E-3, AA p = 0.013, Trans p = 7.44E-5) was a significant multi-tissue 
eQTL in random effects analysis for ADH1B (SFE = 319.4, SHet = 27.6, p = 1.4E-76), 
ADH1A (SFE = 139.4, SHet = 6.6, p = 6.72E-33), and ADH1C (SFE = 167.3, SHet = 8.9, p = 
1.9E-39). Rs10516440 is a LD proxy (r2 > 0.9) of rs6827898 (Table 2) in populations of 
European and African descent. These variants are both located in an intergenic region in the 
ADH gene cluster between ADH1C and ADH7. In line with the fact that the protective 
coding alleles are associated with increased activity of the enzyme encoded by ADH1B, the 
major allele rs10516440*A was associated with increased ADH1B expression and reduced 
AD risk.
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Associations with other GWS loci:
We examined results for the eight independent variants associated at GWS levels with 
alcohol consumption in the UK Biobank17 (Supplementary Table S7). Among the UK 
Biobank findings, three of the four reported variants in the ADH region of chromosome 4 
(rs145452708 – a proxy for rs1229984 with D’=1, rs29001570 and rs35081954) were 
associated in the present study with AD (p ranging from 3.5E-5 – 2.3E-10) with sign 
concordant effects; the remaining variant was excluded from our analysis due to MAF < 
0.01. The UK Biobank lead variant in KLB, rs11940694, was nominally associated with AD 
(p = 0.0097), though this does not surpass multiple testing correction for the eight GWS 
alcohol consumption loci. We see little evidence (p > 0.2) for association of AD with the 
reported loci at GCKR and CADM2, which may be due to differences in power for the given 
effect size or because these genes exert an influence on liability to consume alcohol but not 
later problems. The locus on chromosome 18 showed limited regional association with AD, 
but the index variant was not present in our analysis because it no longer appears in the 1000 
Genomes Phase 3 reference panel21.
Polygenic Risk Score (PRS) analyses:
PRS based on our meta-analysis of AD were significantly predictive of AD outcomes in all 
three tested external cohorts. PRS derived from the unrelated EU GWAS predicted up to 
0.51% of the variance in past month alcohol use disorder in ALSPAC (p = 0.0195; 
Supplementary Figure S10A) and up to 0.3% of problem drinking as indexed by the CAGE 
screener in GS (p = 7.9E-6; Supplementary Figure S10B). PRS derived from the unrelated 
AA GWAS predicted up to 1.7% of the variance in alcohol dependence in the COGA 
AAfGWAS cohort (p = 1.92E-7; Supplementary Figure 10C).
Importantly, PRS derived from the unrelated EU GWAS showed much weaker prediction 
(maximum R2 = 0.37%, p = 0.01; Supplementary Figure S10D) in the COGA AAfGWAS 
than the ancestrally-matched AA GWAS-based PRS despite the much smaller discovery 
sample for AA. In addition, the AD PRS also still yielded significant variance explained 
after controlling for other genetic factors. Prediction of CAGE scores in GS remained 
significant and showed minimal attenuation (R2 = 0.29%, p = 1.0E-5) after conditioning on 
PRS for alcohol consumption derived from UK Biobank results17. In COGA AAfGWAS, the 
AA PRS derived from our study continued to predict 1.6% of the variance in alcohol 
dependence after inclusion of rs2066702 genotype as a covariate, indicating independent 
polygenic effects beyond the lead ADH1B variant (Supplementary Information A14).
Power analysis:
Power analyses indicated that the current meta-analysis is expected to have at least 41% 
power to detect very common variants (MAF ≥ 0.25) with odds ratios ≥ 1.10 at p < 5E-8 and 
63% power for p < 1E-6 (Supplementary Figure S11). Power at p < 1E-6 is relevant because 
only 5 loci reach that threshold in the current meta-analysis. Power is lower for less common 
variants (MAF ≤ 0.05) even with odds ratios ≥ 1.20 at p < 1E-6 (60% power) and p < 5E-8 
(38% power).
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For perspective, power computations using the observed distribution of top effects for other 
large GWAS of polygenic traits suggest that we observe significantly fewer genome-wide 
significant loci for AD than would be expected if the loci had true effect sizes and allele 
frequencies similar to schizophrenia (expected: 25.4 loci, 95% CI 21-30) or obesity 
(expected: 8.9 loci, 95% CI 6-12), but not fewer than would be expected for effect sizes 
similar to major depression (Supplementary Information A10, Supplementary Table S8).
DISCUSSION
To our knowledge, this is the largest GWAS of rigorously-defined AD, comprising 14,904 
AD individuals and 37,944 controls. We identified known loci in ADH1B that differed 
between EU and AA, as well as novel genetic correlations between AD and psychiatric 
disorders (e.g., schizophrenia), tobacco and cannabis use, and social (e.g., socio-economic 
deprivation) and behavioral (e.g., educational attainment) outcomes. Analyses also revealed 
a genetic distinction between GWAS results for alcohol consumption and AD. Although 
larger sample sizes can be amassed by focusing on quantitative measures of consumption, 
only the upper tail is relevant to AD (as a medical diagnosis) and even that does not capture 
other aspects of disordered drinking (e.g., loss of control, withdrawal) directly. Conversely, 
cases derived from electronic medical records (e.g., ICD codes) result in a high rate of false 
negatives, while self-screening instruments (e.g. AUDIT scores) are best suited to analyses 
of disordered drinking when a sufficiently high threshold or score cut-off is applied to focus 
on severity. Our study has the advantage of greater diagnostic precision via use of semi-
structured interviews to diagnose AD systematically in a majority of the constituent studies, 
and therefore greater interpretability in the context of clinically-important AD.
The genome-wide significant SNPs reaffirm the importance of functional variants affecting 
alcohol metabolism to the risk of AD. The top association in ADH1B, rs1229984, is a 
missense variant that is amongst the most widely studied in relation to alcohol use, misuse 
and dependence8–10. The resulting amino acid substitution (Arg48His) increases the rate at 
which alcohol dehydrogenase 1B oxidizes ethanol to acetaldehyde8. Studies on Asian 
populations in which the derived allele is common demonstrated strong protection against 
the development of AD8,9,13. In EU and AA, the protective allele is present at much lower 
frequencies (EU MAF = 0-4%, AA MAF < 1%), nevertheless, recent large-scale studies 
have shown an association between this locus and alcohol consumption and problems at 
GWS levels in EU with similar effect size8–10. The lead variant in AA cohorts, rs2066702 
(Arg370Cys), is another functional missense variant in ADH1B, and it also encodes an 
enzyme with an increased rate of ethanol oxidation8. The allele encoding Cys370 is common 
in AA, but rare in other populations8. Our results clearly show that these two different 
functional SNPs in ADH1B both affect risk for alcoholism, with their relative importance 
dependent upon allele frequency in the population studied. There is a suggestion of 
additional independent effects in the chromosome 4 region, but larger studies will be needed 
to evaluate this.
The only other locus to reach significance was rs7644567 on chromosome 3, primarily 
driven by AA cohorts. The locus failed to replicate in two small, independent AA samples, 
and in the only European cohort with even a modest allele frequency (FINRISK) the effect 
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was in the opposite direction. There have also been discussions about whether the standard 
GWAS significance threshold should be applied to the more genetically diverse African-
ancestry cohorts22,23 and the possibility of confounding from non-linear relationships 
between the phenotype and ancestry-informative markers like rs7644567 in admixed 
samples24, all of which increase our skepticism regarding this finding. There is, therefore, 
insufficient evidence at this time to conclude that rs7644567 is associated with alcohol 
dependence. Analyses of much larger samples of African ancestry will be needed to resolve 
this.
Despite limited SNP-level findings, there is significant evidence for polygenic effects of 
common variants in both EU and AA cohorts. The estimated h2g = 0.09 for AD in EU is 
only modestly lower than those recently reported for alcohol consumption (h2g = 0.13)17 and 
AUDIT scores (h2g = 0.12)18, and comparable to estimates derived for cigarettes-per-day25. 
Our h2g estimate is lower than a prior report7, likely reflecting a combination of differences 
in estimation method (GREML vs. LDSR) and greater heterogeneity in ascertainment 
strategy across samples in the current study (see26–28). The latter is especially relevant in 
comparing h2g from that prior single cohort to our meta-analysis that included cohorts with a 
wide range of ages at ascertainment, cultural environments, and ascertainment strategies, 
including enrichment for other substance use disorders. Similar to other psychiatric 
disorders (e.g. schizophrenia), a much larger sample size will potentially aid in overcoming 
across-sample heterogeneity and capture a greater proportion of genetic variance.
Comparing our GWAS to recent GWAS of alcohol consumption measures suggests that the 
liability underlying normative patterns of alcohol intake and AD are only partially 
overlapping. Genome-wide, genetic correlations were significantly < 1 with log-scaled 
alcohol consumption by participants in AlcGen and CHARGE+ Consortia cohorts16 (rg = 
0.695) and in the UK Biobank17 (rg = 0.371). We also observe only partial replication of the 
8 loci significantly associated with consumption in the UK Biobank, with strongest results 
from SNPs in the ADH region, including a proxy for rs1229984. In addition there was no 
significant correlation with GWAS of log-scaled AUDIT scores in 23andMe participants18 
(rg = 0.076). Subsequent analyses suggest these estimates are sensitive to sample 
characteristics, with somewhat higher genetic correlations reported in analysis of alcohol 
consumption in the full UK Biobank29 (rg = 0.75) and of AUDIT in combined data from 
23andMe participants and UK Biobank30 (rg = 0.39). Importantly, initial UK Biobank data 
inclusion of a subset of participants recruited for a study of smoking and lung function in the 
first analysis17, which may have resulted in collider bias31 and contributed to the initial 
lower genetic correlation.
One key factor in interpreting the differences between these traits and AD is that the 
distribution of consumption levels and AUDIT scores can be highly skewed in population 
samples, with most individuals at the low (non-pathological) end of the spectrum. This effect 
may be especially pronounced among the older, healthy volunteers of the UK Biobank 
cohort32 and in the 23andMe cohort, which is more educated and has higher socioeconomic 
status than the general US population18. We hypothesize that the variants that affect 
consumption at lower levels may differ substantively from those that affect very high levels 
of consumption in alcohol dependent individuals, who are also characterized by loss of 
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control over intake33. This appears to be the case in studies that used specific cut-offs to 
harmonize AUDIT scores with AD data30,34. The larger of these studies30 reports that the 
genetic correlation between AD and AUDIT scores is maximized at an AUDIT cutoff ≥ 20 
(with controls defined as those scoring ≤ 4; rg = 0.90). Interestingly, that study also found 
that a score reflecting items related to problem drinking (AUDIT-P) resulted in a stronger 
genetic correlation (rg = 0.64) than a score related to alcohol consumption alone (rg = 0.33). 
The strong genetic correlation of AD with lower educational attainment and lower socio-
economic status (i.e. higher Townsend deprivation), in contrast to positive genetic 
correlations of education with consumption17 and AUDIT scores related to consumption30, 
further underscore this distinction between normative/habitual levels of alcohol intake and 
diagnosed AD, at least in the respective populations studied.
The current analysis identified robust genetic correlation of AD with a broad variety of 
psychiatric outcomes. This correlation is strongest for aspects of negative mood, including 
neuroticism and major depression, as also seen in twin studies35,36 and through recent 
specific molecular evidence for pleiotropy37,38. Taken together with evidence from other 
recent genomic studies37, and null correlations for other GWAS of alcohol consumption, but 
not for measures of problem drinking (e.g., AUDIT-P), these findings suggest that major 
depression may primarily share genetic liability with alcohol use at pathological levels.
AD was also strongly genetically correlated with poor educational and socioeconomic 
outcomes, and marginally correlated with measures of risk-taking. Nominally significant 
genetic correlations with delay discounting (i.e. favoring immediate rewards), risk-taking, 
and the strong genetic correlation of AD with ADHD, cigarette smoking and cannabis use 
may similarly reflect a shared genetic factor for risk-taking and reduced impulse control. 
Common genetic liability to early, risky behaviors is characteristic of both AD39 and age of 
first birth40. The observed negative genetic correlation with age of first birth is consistent 
both with risk-taking and with the significant genetic correlations of AD with lower 
socioeconomic status, as indexed by higher neighborhood Townsend deprivation score, and 
lower educational attainment. Lower socioeconomic status is correlated with both AD41 and 
age at first birth42 and the current study suggests that shared genetic liabilities may be one 
potential mechanism for their observed relationship. However, the question of whether these 
genetic correlations represent causal processes, horizontal pleiotropy, or the impact of 
unmeasured confounders should be explored in the future43.
Lower genetic correlations were observed for most biomedical and anthropometric 
outcomes. Liver enzymes GGT and ALT, once proposed as possible biomarkers for alcohol 
abuse44, showed only nominal evidence for genetic correlation with AD and neither survived 
multiple testing correction. Notably, we did not find any association between AD and body-
mass index (BMI). Negative genetic correlations with BMI were previously reported for 
both alcohol consumption17 and AUDIT scores18, but there is prior evidence that BMI has 
differing underlying genetic architecture in the context of AD and outside of that context45. 
The negative genetic correlations observed in those studies are consistent with studies of 
light to moderate drinking, which is also associated with healthier lifestyle behaviors, while 
heavy and problematic drinking is typically associated with weight gain46.
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This study benefits from precision in diagnostic assessment of AD, known alcohol exposure 
in a majority of the controls, and careful quality control that excluded overlap of individuals 
between studies. Despite these strengths, our sample size was insufficient to identify 
additional GWS loci robustly. Power analyses indicate that additional SNPs associated with 
AD are likely to have small effect sizes, smaller than schizophrenia47 and more consistent 
with more common psychiatric disorders (e.g. major depression48). This supports the 
pressing need for collection of large numbers of well characterized cases and controls. The 
differences between our results and the study of AUDIT scores18 highlight that 
ascertainment and trait definition are critically important and must be taken into account. 
Careful study of how screening tools, such as the AUDIT, correlate to genetic liability to AD 
(as defined by DSM-IV or similar) could substantially boost sample sizes for future AD 
GWAS. There is also a continued need to characterize the genetic architecture of AD in non-
EU populations.
We show a novel genetic distinction between drinking in the pathological range (AD) and 
habitual drinking that does not cross the threshold into pathology or dependence nor 
captures behavioral aspects of disordered drinking. Larger future samples will allow us to 
uncover additional pleiotropy between pathological and non-pathological alcohol use as well 
as between AD and other neuropsychiatric disorders.
METHODS
Samples:
The Substance Use Disorders working group of the Psychiatric Genomics Consortium 
(PGC-SUD14) collected individual genotypic data from 14 case/control studies and 9 family-
based studies and summary statistics from GWAS of AD from 5 additional cohorts (Table 
1). AD was defined as meeting criteria for a DSM-IV2 (or, for one cohort, DSM-IIIR50; a 
very similar construct; Supplementary Note B1) diagnosis of AD. Diagnoses were derived 
either from clinician ratings or semi-structured interviews. Excepting three cohorts with 
population-based controls (N=7,015), all controls were screened for AD. Individuals with no 
history of drinking alcohol and those meeting criteria for DSM-IV alcohol abuse were 
excluded as controls where possible (Supplementary Information A1; Life Sciences 
Reporting Summary). This study was approved by the institutional review board (IRB) of 
Washington University in St. Louis and was conducted in accordance with all relevant 
ethical regulations. Each contributing cohort obtained informed consent from their 
participants and received ethics approvals of their study protocols from their respective 
review boards in accordance with applicable regulations.
Quality Control and Imputation:
Data for the cohorts that shared raw genotypes were deposited to a secure server for uniform 
quality control (QC). QC and imputation of the 14 case/control studies was performed using 
the ricopili pipeline (https://github.com/Nealelab/ricopili). For the 9 family-based cohorts, 
an equivalent pipeline, picopili (https://github.com/Nealelab/picopili), was developed for 
QC, imputation, and analysis appropriate for diverse family structures, including twins, 
sibships and extended pedigrees (Supplementary Information A2).
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After initial sample and variant QC, principal components analysis (PCA) was used to 
identify population outliers for exclusion and to stratify samples in each study by continental 
ancestry. Identified EU and AA ancestry populations were confirmed by PCA using the 
1000 Genomes reference panel21 (Supplementary Figure S12). Ancestry within these 2 
groups was accounted for with principal components. Final sample and variant QC, 
including filters for call rate, heterozygosity, and departure from Hardy-Weinberg 
equilibrium (HWE), was then performed within each ancestry group in each cohort. Samples 
were also filtered for cryptic relatedness and for departures from reported pedigree structures 
(Supplementary Information A3; Life Sciences Reporting Summary).
Each cohort was imputed using SHAPEIT51 and IMPUTE252, using the cosmopolitan (all 
ancestries) 1000 Genomes reference panel consistent with prior recommendations53 (see 
also47,54,55). Concordance of minor allele frequencies (MAF) with the reference panel was 
verified prior to imputation, with SNPs in EU cohorts compared to MAF in European 
population samples and AA cohorts compared to MAF in African population samples 
(Supplementary Information A4). Cryptic relatedness between cohorts was excluded after 
imputation (Supplementary Information A5). Imputed SNPs were then filtered for INFO 
score > 0.8 and allele frequency > 0.01 prior to analysis.
Association Analysis:
A GWAS of AD status was performed within each ancestry stratum of each sample using an 
association model appropriate for the study design (Table 1, Supplementary Table S1). For 
case/control studies, GWAS was performed using logistic regression with imputed dosages. 
For family-based studies of small, simple pedigrees (e.g., sibships), association with imputed 
genotypes was tested using generalized estimating equations (GEE). For more complex 
pedigrees, imputed genotypes were tested using logistic mixed models. Sex was included as 
a covariate, along with principal components to control for population structure 
(Supplementary Information A6, Supplementary Note B2, Supplementary Figures S13–
S14).
In addition to this primary analysis, subsets of genetically unrelated individuals were 
selected from each family-based cohort (i.e. the most severe case in each family, by 
symptom count, was selected, followed by selection of unrelated/married-in controls) and 
used to perform a conventional case/control GWAS using logistic regression. This was used 
in place of the family-based GWAS for estimation of effect sizes and LD score regression 
analyses (Supplementary Table S2).
Genome-wide Meta-Analysis:
The primary discovery meta-analysis of all ancestry-stratified GWAS (Ncase = 14,904; 
Ncontrol = 37,944) was conducted in METAL56. As the different study designs (family vs. 
case-control) produced effect sizes that were not comparable, results were combined using 
weighting by effective sample size (Supplementary Information A7, Supplementary Note 
B3). Separate ancestry-specific discovery meta-analyses of EU (N = 46,568) and AA (N = 
6,280) cohorts were also performed. Heterogeneity was evaluated across all cohorts and 
between study designs (Supplementary Information A8).
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In addition to the discovery meta-analyses, we conducted meta-analyses for two design 
subsets. First, we performed sample size weighted meta-analysis of the subset of genetically 
unrelated individuals in EU (N = 38,686) and AA (N = 5,799) cohorts for use in LD score 
regression (LDSR) analysis. Second, we performed inverse-variance weighted meta-analysis 
of genetically unrelated individuals in genotyped cohorts to estimate within-ancestry effect 
sizes for EU (N = 28,757) and AA (N = 5,799). These effect sizes were then used to 
compare trans-ancestral fine mapping results using inverse-variance weighted fixed effects, 
random effects57, and Bayesian58 models (Supplementary Information A7). Supplementary 
Table S2 summarizes all of the meta-analytic models considered in the current analysis.
Replication:
As described below, a novel locus on chromosome 3 was genome-wide significant (GWS) in 
the trans-ancestral discovery meta-analysis. To seek replication, we examined the association 
between this locus and DSM-IV AD in two independent AA samples: Yale-Penn 2 (911 
cases, 599 controls; tested using GEE) and COGA AAfGWAS (880 cases, 1,814 controls; 
tested using GWAF59). Association with AD status, broadly defined using hospital and death 
records, was also examined in the FINRISK cohort (1,232 cases, 22,614 controls) using 
Firth logistic regression60 (Supplementary Information A1.4; Life Sciences Reporting 
Summary).
Power Analysis:
Post-hoc power analysis was performed for odds ratios ranging from 1.05 to 1.30 and across 
allele frequencies using CaTS61 with the estimated effective sample size. Power analysis 
identifies the range of SNP effect sizes the current study was likely to detected at genome-
wide significance if such effects exist. Additionally, we made specific comparisons to the 
distribution of effects for schizophrenia47, obesity62 and major depression48 as meaningful 
benchmarks to understand the magnitude of effect sizes plausible for AD (Supplementary 
Information A10; Life Sciences Reporting Summary).
Heritability and Genetic Correlation Analysis:
LDSR analysis63 was performed to estimate the heritability explained by common SNPs in 
meta-analyses of unrelated EU and AA samples, respectively. LDSR was performed using 
HapMap3 SNPs and LD scores computed from 1000 Genomes reference samples 
corresponding to each population (Supplementary Information A11). Conversion of h2g 
estimates from observed to liability scale64 was performed assuming population prevalences 
of 0.159 and 0.111 for AD in alcohol-exposed EU and AA individuals, respectively3. Gene-
level enrichments were also tested with MAGMA15 (Supplementary Information A12).
Genetic correlation between AD and 45 traits from LD Hub25 and other published 
studies16–19,65–71 was examined using LDSR with the same unrelated EU meta-analysis 
(10,206 cases and 28,480 controls) and precomputed European LD scores. LDSR compares 
GWAS results for pairs of traits to estimate the correlation in the genetic liabilities explained 
by all common SNPs in the LD reference panel. To avoid increasing the multiple testing 
burden, redundant or highly-correlated phenotypes were reduced by manually selecting the 
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version of the phenotype with the greatest predicted relevance to AD, largest sample size, or 
highest heritability (Supplementary Information A13).
Polygenic Risk Scores:
To test the generalizability of the current GWAS results, polygenic risk scores (PRS) were 
computed in three external cohorts (Supplementary Information A1.5; Life Sciences 
Reporting Summary). PRS computed from EU ancestry results were used to predict alcohol 
dependence in ALSPAC72,73 and COGA AAfGWAS, and CAGE screener scores in 
Generation Scotland (GS)74. PRS based upon the AA results were used to predict alcohol 
dependence in COGA AAfGWAS (Supplementary Information A14).
Data availability:
Summary statistics from the genome-wide meta-analyses are available on the Psychiatric 
Genomics Consortium’s downloads page (http://www.med.unc.edu/pgc/results-and-
downloads), including the source data for Figures 1 and 2. Individual-level data from the 
genotyped cohorts and cohort-level summary statistics will be made available to researchers 
following an approved analysis proposal through the PGC Substance Use Disorder group 
with agreement of the cohort PIs; contact the corresponding authors for details. Cohort data 
are also available from dbGaP except where prohibited by IRB or European Union data 
restrictions. Expression data used to evaluate variants in ADH1B is available from GTEx 
(https://gtexportal.org/home/). Hi-C data used to evaluate the chromosome 3 variant can be 
queried with HUGIn (https://yunliweb.its.unc.edu/hugin/). Publicly available genome-wide 
summary statistics used for testing genetic correlations are accessible through LD Hub 
(http://ldsc.broadinstitute.org/), or from the Psychiatric Genomics Consortium (http://
www.med.unc.edu/pgc/results-and-downloads), the Social Science Genetic Association 
Consortium (SSGAC; https://www.thessgac.org/data), Enhancing Neuro Imaging Genetics 
through Meta Analysis (ENIGMA; http://enigma.ini.usc.edu/research/download-enigma-
gwas-results/), and the Neale Lab (http://www.nealelab.is/uk-biobank); for availability of 
summary statistics from other studies contact the respective authors. The source data for 
Figure 3 is included in Supplementary Table S6.
Code availability:
Code for GWAS of case/control cohorts with ricopili is available at https://github.com/
Nealelab/ricopili. Code for GWAS of family-based cohorts with picopili is available at 
https://github.com/Nealelab/picopili. Code and reference data for LD score regression 
analyses are available at https://github.com/bulik/ldsc. Effective sample size calculations 
were implemented using output from PLINK (https://www.cog-genomics.org/plink2), and 
GMMAT (https://content.sph.harvard.edu/xlin/software.html#gmmat) and geepack (https://
cran.r-project.org/web/packages/geepack/index.html) in R (https://cran.r-project.org/); stand-
alone software for this purpose hasn’t been written but example code is available from the 
first author by request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Christchurch Health and Development Study (CHDS): dbGAP submission in process
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Study of Addiction: Genetics and Environment (SAGE): dbGAP accession phs000092.v1.p1
Collaborative Genetic Study of Nicotine Dependence (COGEND): dbGAP accession 
phs000404.v1.p1
Gene-Environment-Development Initiative (GEDI) – Duke University (GSMS): dbGAP 
accession phs000852.v1.p1
Center on Antisocial Drug Dependence (CADD): dbGAP submission in process
Spit for Science: dbGAP submission in process
NIAAA: available via https://btris.nih.gov/
Gene-Environment-Development Initiative (GEDI) –Virginia Commonwealth University 
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phs000620.v1.p1
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See Data Availability for information on accessing other cohorts.
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Figure 1: Manhattan plot of discovery trans-ancestral meta-analysis showing strong evidence for 
rs1229984 in ADH1B.
Results from the discovery meta-analysis of all cohorts (Ncase=14,904, Ncontrol=37,944) for 
association of genome-wide SNPs with AD under a fixed effects meta-analysis weighted by 
effective sample size. Dashed red reference line indicates genome-wide significance after 
correction for multiple testing (p < 5E-8).
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Figure 2: Regional plots for the ADH1B locus (rs1229984) in the trans-ancestral discovery, 
African-American (AA), and European (EU), meta-analyses.
Results of fixed effects meta-analysis with effective sample size weights for the ADH1B 
locus in (A) all cohorts (Ncase=14,904, Ncontrol=37,944); (B) AA cohorts (Ncase=3,335, 
Ncontrol=2,945); and (C) EU cohorts (Ncase=11,569, Ncontrol=34,999). Red reference line 
indicates the genome-wide significance threshold after correction for multiple testing within 
each analysis (p < 5E-8). Within ancestry, colored points reflect the degree of LD (pairwise 
r2) to the index variant (indicated by a purple diamond) in 1000 Genomes Project reference 
data21 for individuals of (B) African or (C) European ancestry, respectively. LD structures in 
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the two ancestries differ, so for the trans-ancestral sample (A) LD is not given, indicted by 
gray points. Two-tailed tests used for all analyses.
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Figure 3: Genetic correlations between 45 traits and alcohol dependence in Europeans.
Genetic correlation results from LD score regression (LDSR) with the meta-analysis of AD 
in unrelated EU individuals (Ncase=10,206, Ncontrol=28,480). After Bonferroni correction, 
significant correlations are observed with 17 traits and disorders (p < 1.1E-3; bold), with 
nominally significant results for 8 additional traits and disorders (p < .05; italics) based on 
two-tailed tests of the estimated genetic correlation with block jackknife standard errors. 
Error bars indicate 95% confidence intervals, with arrows indicating intervals extending 
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above 1 or below −1. Vertical gray reference line corresponds to the null hypothesis of no 
genetic correlation with AD. Phenotypes are organized by research domain.
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